Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure

Open access
Gallo, Pasquale, Latronico, Michael V.G., Gallo, Paolo, Grimaldi, Serena, Borgia, Francesco, Todaro, Matilde, Jones, Philip, Gallinari, Paola, De Francesco, Raffaele, Ciliberto, Gennaro, Steinkühler, Christian, Esposito, Giovanni, Condorelli, Gianluigi · 2008 · Cardiovascular Research

Abstract

AIMS: Recent studies have demonstrated the importance of chromatin remodelling via histone acetylation/deacetylation for the control of cardiac gene expression. Specific histone deacetylases (HDACs) can, in fact, play a positive or negative role in determining cardiac myocyte (CM) size. Here, we report on the effect on hypertrophy development of three inhibitors (HDACi) of class I HDACs. METHODS AND RESULTS: The compounds were first analysed in vitro by scoring hypertrophy, expression of foetal genes, and apoptosis of neonatal rat CMs stimulated with phenylephrine, an alpha1-adrenergic agonist. This initial screening indicated that a truncated derivative of apicidin with class I HDAC specificity, denoted API-D, had the highest efficacy to toxicity ratio, and was thus selected for further analysis in vivo. Administration of this drug significantly decreased myocardial hypertrophy and foetal gene expression after 1 week of pressure overload induced by thoracic aortic constriction (TAC) in mice. After 9 weeks of TAC, when manifest heart failure is encountered, mice treated with API-D presented with significantly improved echocardiographic and haemodynamic parameters of cardiac function when compared with untreated TAC-operated mice. CONCLUSION: The apicidin derivative, API-D, is capable of reducing hypertrophy and, consequently, the transition to heart failure in mice subjected to TAC. Treatment with this substance, therefore, holds promise as an important therapeutic option for heart failure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cvr/cvn215

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 170

Metadata

Authors
Gallo, P., Latronico, M. V. G., Gallo, P., Grimaldi, S., Borgia, F., Todaro, M., Jones, P., Gallinari, P., De Francesco, R., Ciliberto, G., Steinkühler, C., Esposito, G., & Condorelli, G.
Venue
Cardiovascular Research
Published
2008-08-12
Volume
80
Issue
3
Pages
416-424
ISSN
  • 0008-6363 (ISSN-L)
  • 1755-3245
OpenAlex
W2040645204
Cited by
170
References
4
FWCI
2.61
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. https://app.cochat.ai/papers/10.1093/cvr/cvn215
The paper
Gallo, P., Latronico, M. V. G., Gallo, P., Grimaldi, S., Borgia, F., Todaro, M., Jones, P., Gallinari, P., De Francesco, R., Ciliberto, G., Steinkühler, C., Esposito, G., & Condorelli, G. (2008). Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovascular Research. https://doi.org/10.1093/cvr/cvn215

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.